Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647168 | 0.90 | CHRNA7 (0.34) | CHRNA7CYP19A1CYP11B1CYP11B2PDE4B | |
| SCHEMBL3927311 | 0.89 | CYP19A1 (0.36) | CHRNA7CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL647136 | 0.89 | CHRNA7 (0.34) | CHRNA7CYP19A1CYP11B1CYP11B2PDE4B | |
| SCHEMBL646575 | 0.88 | CYP19A1 (0.35) | CHRNA7CYP19A1CYP11B1CYP11B2PKM | |
| SCHEMBL646477 | 0.87 | MAOA (0.36) | CHRNA7CYP19A1CYP11B1CYP11B2PKM | |
| SCHEMBL646204 | 0.86 | SIRT2 (0.36) | CHRNA7CYP19A1CYP11B1CYP11B2MAPK14 | |
| SCHEMBL649516 | 0.86 | MTNR1A (0.35) | CHRNA7CYP19A1CYP11B1CYP11B2HTR6 | |
| SCHEMBL3929644 | 0.85 | MAOB (0.37) | PRKDC | |
| SCHEMBL3919076 | 0.84 | MTNR1A (0.38) | CHRNA7CYP19A1CYP11B1CYP11B2APP | |
| SCHEMBL3920272 | 0.84 | FFAR4 (0.46) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | CHRNA7 4025/4885CYP19A1 1947/4885CYP11B1 1789/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | CHRNA7 4726/4885CYP19A1 1354/4885CYP11B1 1623/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | CHRNA7 4658/4885CYP19A1 945/4885CYP11B1 3262/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | CHRNA7 4179/4885CYP19A1 4256/4885CYP11B1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.